A 14-year longitudinal study of neurofilament light chain dynamics in premanifest and transitional Huntington’s disease
Authors:
Open Access
- 3 October 2024
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (12) , 7572-7582
Abstract
Background: Growing evidence supports the value of neurofilament light (NfL) as a prognostic biomarker in premanifest Huntington’s disease (HD). To date, however, there has been no longitudinal study exceeding 3 years examining either its serial dynamics or predictive power in HD. We aimed to conduct the first such study. Methods: Serum NfL was sampled using ultrasensitive immunoassay at four timepoints across a 14-year period in a cohort of HD gene carriers (n = 21) and controls (n = 14). Gene carriers were premanifest at baseline. Clinical features of HD were evaluated by Unified Huntington’s Disease Rating Scale (UHDRS TMS), Montreal Cognitive Assessment (MoCA), Trail A/B task, Symbol Digit Modalities Task and semantic/phonemic fluency tasks. Results: 14/21 HD gene carriers converted to prodromal or manifest disease by the final timepoint (“converters”). At baseline and each subsequent timepoint, NfL levels were higher in converters than in non-converters and controls (p = < 0.001–0.03, ηp2 = 0.25–0.66). The estimated rate of change in NfL was higher in converters than in non-converters (p = 0.03) and controls (p = 0.001). Baseline NfL was able to discriminate converters from non-converters (area under curve = 1.000, p = 0.003). A higher rate of change in NfL was predictive of more severe motor (UHDRS-TMS p = 0.007, β = 0.711, R2 = 0.468) and cognitive deficits (MoCA p = 0.007, β = − 0.798, R2 = 0.604; Trail B, p = 0.007, β = 0.772, R2 = 0.567; phonemic fluency p = 0.035, β = − 0.632, R2 = 0.345). Conclusions: Our data suggest that (1) NfL longitudinal dynamics in premanifest/transitional HD are non-constant; rising faster in those closer to disease onset, and (2) NfL can identify individuals at risk of conversion to manifest disease and predict clinical trajectory, > 10 years from disease onset.Keywords
Funding Information
- Guarantors of Brain
- Cambridge Centre for Parkinson-Plus
- Cure Parkinson's Trust
- Race Against Dementia
- Alzheimer’s Research UK
- Medical Research Council
- Wellcome Trust
- UK Research and Innovation
- NIHR Cambridge Biomedical Research Centre
This publication has 36 references indexed in Scilit:
- Serum neurofilament light chain in progressive supranuclear palsyParkinsonism & Related Disorders, 2018
- Predicting clinical diagnosis in Huntington's disease: An imaging polymarkerAnnals of Neurology, 2018
- Neurofilament light protein in blood predicts regional atrophy in Huntington diseaseNeurology, 2018
- Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysisThe Lancet Neurology, 2017
- Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?PLOS ONE, 2017
- Validation of a prognostic index for Huntington's diseaseMovement Disorders, 2016
- The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive ImpairmentJournal of the American Geriatrics Society, 2005
- A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG lengthClinical Genetics, 2004
- Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onsetProceedings of the National Academy of Sciences, 2004
- The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's diseaseNature Genetics, 1993